Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy

被引:9
|
作者
El Beshlawy, Amal [1 ]
Murugesan, Vagishwari [2 ]
Mistry, Pramod Kumar [3 ]
Eid, Khaled [1 ]
机构
[1] Cairo Univ, Dept Pediat, Pediat Hematol, Giza, Egypt
[2] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA
[3] Yale Univ, Internal Med & Pediat, Sch Med, 333 Cedar St,LMP 1080,POB 208019, New Haven, CT 06520 USA
关键词
Gaucher disease; Hepatopulmonary syndrome; Enzyme replacement therapy; Pulmonary complications; PULMONARY-HYPERTENSION; PHENOTYPE; DETERMINANTS; ASSOCIATION; CELLS;
D O I
10.1016/j.ymgmr.2019.100490
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Advanced liver disease complicated by hepatopulmonary syndrome is a recognized complication of Gaucher disease. Macrophage-targeted, recombinant enzyme replacement therapy is effective in reversing clinical manifestations attributed to the accumulation of glycolipid-laden macrophages but it is not known whether advanced fibrotic features of the disease can be ameliorated. We describe a splenectomized patient with Gaucher disease who developed massive hepatomegaly, cirrhosis of the liver and life-threatening hepatopulmonary syndrome. Treatment with Imiglucerase enzyme replacement therapy resulted in dramatic reversal of hepatopulmonary syndrome and liver disease. Our report suggests that Gaucher disease pathology involving advanced fibrosis and life-threatening complications can be reversed by imiglucerase enzyme therapy. Synopsis: Effect of imiglucerase enzyme replacement therapy on Hepatopulmonary Syndrome in Gaucher Disease.
引用
收藏
页数:4
相关论文
共 50 条
  • [21] Immunomodulation in Pompe disease: an effective strategy to resume enzyme replacement therapy after life-threatening adverse reactions
    Kern, I
    Caubet, J. C.
    Filaine, P.
    Ruchonnet-Metrailler, I
    Rimensberger, P.
    Corbelli, R.
    SWISS MEDICAL WEEKLY, 2016, 146 : 28S - 28S
  • [22] Enzyme replacement therapy for Gaucher disease in Australia
    Goldblatt, J
    Szer, J
    Fletcher, JM
    McGill, J
    Rowell, JA
    Wilson, M
    INTERNAL MEDICINE JOURNAL, 2005, 35 (03) : 156 - 161
  • [23] Interruption of enzyme replacement therapy in Gaucher disease
    Goldblatt, J.
    Fletcher, J. M.
    McGill, J.
    Szer, J.
    Wilson, M.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2016, 106 (06): : S79 - S81
  • [24] Cessation of enzyme replacement therapy in Gaucher disease
    Grinzaid, KA
    Geller, E
    Hanna, SL
    Elsas, LJ
    GENETICS IN MEDICINE, 2002, 4 (06) : 427 - 433
  • [25] Interruption in enzyme replacement therapy for Gaucher disease
    Weinreb, NJ
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) : 1087 - 1088
  • [26] ENZYME REPLACEMENT THERAPY OF INFANTILE GAUCHER DISEASE
    ERIKSON, A
    JOHANSSON, K
    MANSSON, JE
    SVENNERHOLM, L
    NEUROPEDIATRICS, 1993, 24 (04) : 237 - 238
  • [27] GAUCHER DISEASE - EFFICACY OF ENZYME REPLACEMENT THERAPY
    FALLET, S
    GRABOWSKI, GA
    AMERICAN JOURNAL OF HUMAN GENETICS, 1991, 49 (04) : 113 - 113
  • [28] Enzyme replacement therapy for Gaucher's disease
    Beutler, E
    BAILLIERES CLINICAL HAEMATOLOGY, 1997, 10 (04): : 751 - 763
  • [29] Management of Gaucher Disease: Enzyme Replacement Therapy
    Zimran, Ari
    Elstein, Deborah
    PEDIATRIC ENDOCRINOLOGY REVIEWS PER, 2014, 12 : 82 - 87
  • [30] Recombinant Glucocerebrosidase (Imiglucerase) as a Therapy for Gaucher Disease
    Pastores, Gregory M.
    BIODRUGS, 2010, 24 (01) : 41 - 47